Pharmacokinetics and Exposure-Response of Vosoritide in Children with Achondroplasia.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
accepted:
11
07
2021
pubmed:
26
8
2021
medline:
26
4
2022
entrez:
25
8
2021
Statut:
ppublish
Résumé
Vosoritide, an analog of C-type natriuretic peptide, has been developed for the treatment of children with achondroplasia. The pharmacokinetics of vosoritide and relationships between plasma exposure and efficacy, biomarkers, and safety endpoints were evaluated in a phase II, open-label, dose-escalation study (N = 35 patients aged 5-14 years who received daily subcutaneous injections for 24 months) and a phase III, double-blind, placebo-controlled study (N = 60 patients aged 5-18 years randomized to receive daily subcutaneous injections for 52 weeks). Pharmacokinetic parameters for both studies were obtained from non-compartmental analysis. Potential correlations between vosoritide exposure and changes in annualized growth velocity, collagen type X marker (CXM; a biomarker of endochondral ossification), cyclic guanosine monophosphate (cGMP; a biomarker of pharmacological activity), heart rate, and systolic and diastolic blood pressures were then evaluated. The exposure-response relationships for changes in both annualized growth velocity and the CXM biomarker saturated at 15 μg/kg, while systemic pharmacological activity, as measured by urinary cGMP, was near maximal or saturated at exposures obtained at the highest dose studied (i.e. 30 μg/kg). This suggested that the additional bioactivity was likely in tissues not related to endochondral bone formation. In the phase III study, following subcutaneous administration at the recommended dose of 15 μg/kg to patients with achondroplasia aged 5-18 years, vosoritide was rapidly absorbed with a median time to maximal plasma concentration (C The results support the recommended dose of vosoritide 15 µg/kg for once-daily subcutaneous administration in patients with achondroplasia aged ≥ 5 years whose epiphyses are not closed. NCT02055157, NCT03197766, and NCT01603095.
Sections du résumé
BACKGROUND AND OBJECTIVE
Vosoritide, an analog of C-type natriuretic peptide, has been developed for the treatment of children with achondroplasia. The pharmacokinetics of vosoritide and relationships between plasma exposure and efficacy, biomarkers, and safety endpoints were evaluated in a phase II, open-label, dose-escalation study (N = 35 patients aged 5-14 years who received daily subcutaneous injections for 24 months) and a phase III, double-blind, placebo-controlled study (N = 60 patients aged 5-18 years randomized to receive daily subcutaneous injections for 52 weeks).
METHODS
Pharmacokinetic parameters for both studies were obtained from non-compartmental analysis. Potential correlations between vosoritide exposure and changes in annualized growth velocity, collagen type X marker (CXM; a biomarker of endochondral ossification), cyclic guanosine monophosphate (cGMP; a biomarker of pharmacological activity), heart rate, and systolic and diastolic blood pressures were then evaluated.
RESULTS
The exposure-response relationships for changes in both annualized growth velocity and the CXM biomarker saturated at 15 μg/kg, while systemic pharmacological activity, as measured by urinary cGMP, was near maximal or saturated at exposures obtained at the highest dose studied (i.e. 30 μg/kg). This suggested that the additional bioactivity was likely in tissues not related to endochondral bone formation. In the phase III study, following subcutaneous administration at the recommended dose of 15 μg/kg to patients with achondroplasia aged 5-18 years, vosoritide was rapidly absorbed with a median time to maximal plasma concentration (C
CONCLUSIONS
The results support the recommended dose of vosoritide 15 µg/kg for once-daily subcutaneous administration in patients with achondroplasia aged ≥ 5 years whose epiphyses are not closed.
CLINICAL TRIALS REGISTRATION
NCT02055157, NCT03197766, and NCT01603095.
Identifiants
pubmed: 34431071
doi: 10.1007/s40262-021-01059-1
pii: 10.1007/s40262-021-01059-1
pmc: PMC8813707
doi:
Substances chimiques
Biomarkers
0
Natriuretic Peptide, C-Type
127869-51-6
vosoritide
7SE5582Q2P
Banques de données
ClinicalTrials.gov
['NCT03197766', 'NCT02055157', 'NCT01603095']
Types de publication
Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
263-280Informations de copyright
© 2021. The Author(s).
Références
Endocr Rev. 2000 Feb;21(1):23-39
pubmed: 10696568
Endocrinology. 2009 Jul;150(7):3138-44
pubmed: 19282381
Nat Rev Endocrinol. 2018 May;14(5):285-300
pubmed: 29546874
Proc Natl Acad Sci U S A. 2001 Mar 27;98(7):4016-21
pubmed: 11259675
Hum Mutat. 2012 Jan;33(1):29-41
pubmed: 22045636
FEBS J. 2011 Jun;278(11):1808-17
pubmed: 21375692
Eur J Pediatr. 2017 Jul;176(7):873-879
pubmed: 28501952
Am J Med Genet A. 2015 May;167A(5):1033-8
pubmed: 25728306
Endocr J. 2010;57(8):659-66
pubmed: 20567091
Orthod Craniofac Res. 2005 Feb;8(1):11-7
pubmed: 15667640
J Cell Sci. 2005 Nov 1;118(Pt 21):5089-100
pubmed: 16234329
J Med Genet. 1998 Sep;35(9):705-12
pubmed: 9733026
J Orthop. 2015 Jan 28;12(1):31-4
pubmed: 25829758
Handb Exp Pharmacol. 2009;(191):341-66
pubmed: 19089336
Am J Med Genet A. 2019 Sep;179(9):1745-1755
pubmed: 31240834
AAPS J. 2015 Jan;17(1):134-43
pubmed: 25366889
Nat Med. 2004 Jan;10(1):80-6
pubmed: 14702637
Hum Mutat. 2007 Jul;28(7):724-31
pubmed: 17373680
Hum Mutat. 2007 Dec;28(12):1183-8
pubmed: 17676597
Lancet. 2007 Jul 14;370(9582):162-172
pubmed: 17630040
Acta Paediatr. 2013 Aug;102(8):787-96
pubmed: 23586744
J Pharmacol Exp Ther. 2015 Apr;353(1):132-49
pubmed: 25650377
Sci Transl Med. 2017 Dec 6;9(419):
pubmed: 29212713
Clin Perinatol. 2015 Jun;42(2):301-19, viii
pubmed: 26042906
J Clin Endocrinol Metab. 2021 Jan 1;106(1):e255-e264
pubmed: 33034649
J Pediatr Endocrinol Metab. 2020 Nov 12;33(12):1589-1595
pubmed: 33180038
Development. 2015 Mar 1;142(5):817-31
pubmed: 25715393
Clin Genet. 2013 Sep;84(3):237-43
pubmed: 23106480
Horm Res Paediatr. 2016;86(1):27-34
pubmed: 27355624
Am J Hum Genet. 2012 Dec 7;91(6):1108-14
pubmed: 23200862
Arch Dis Child. 2012 Feb;97(2):129-34
pubmed: 21460402
N Engl J Med. 2019 Jul 4;381(1):25-35
pubmed: 31269546
Lancet. 2020 Sep 5;396(10252):684-692
pubmed: 32891212
Am J Med Genet. 1998 Jun 16;78(1):30-5
pubmed: 9637420
AAPS J. 2012 Jun;14(2):296-302
pubmed: 22407289
J Dev Behav Pediatr. 2010 Jan;31(1):41-7
pubmed: 20081435
Clin Pharmacokinet. 2013 Oct;52(10):855-68
pubmed: 23719681
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17300-5
pubmed: 15572448
Am J Med Genet A. 2018 Sep;176(9):1819-1829
pubmed: 30152086
Biomed Pharmacother. 2017 Aug;92:826-835
pubmed: 28599248
Am J Clin Nutr. 2008 Aug;88(2):364-71
pubmed: 18689372
Am J Physiol Endocrinol Metab. 2009 Dec;297(6):E1339-48
pubmed: 19808910
J Pediatr Endocrinol Metab. 2001 Jan;14(1):17-26
pubmed: 11220700